Fig. 3
From: The majority of β-catenin mutations in colorectal cancer is homozygous
E-cadherin and β-catenin expression in colorectal cancer cell lines DLD1 (CTNNB1 wt/wt), HCT116 (CTNNB1 S45del/wt), and LS180 (CTNNB1 S45F/S45F). a Strongly reduced E-cadherin expression in LS180 as compared to DLD1 and HCT116. b E-cadherin and β-catenin immunoflourescence staining showing reduced levels and aberrant membranous localization of E-cadherin only for LS180 cells Distinct membranous colocalization of E-cadherin and β-catenin in DLD1 and HCT116 (long white arrows) and dot-like discontinuous expression of E-cadherin and β-catenin in LS180 (short arrows), (original magnification ×400). c Immunohistochemistry of E-cadherin in tumour samples from CRC patients. Upper image. Tumour specific (T) reduction of E-cadherin expression in comparison to non neoplastic crypts (N) in a CTNNB1 wildtype CRC. Lower image: Normal tumor specific E-cadherin expression in a CTNNB1 mutated CRC (original magnification × 200)